$1,000 – $3,000 Paid Clinical Trials
440 studies
Standard inpatient Phase 1 studies with multi-day residential stays typically compensate $1,000–$3,000.
Compensation amounts shown are typical ranges for this study type — not guaranteed amounts. Actual compensation is set by each study sponsor and documented in the informed consent form. ClinicalTrials.gov does not include a structured compensation field.
Showing 161–180 of 440 studies
Recruiting
Phase 1Phase 2
To studyJUV-161 Administered to Healthy Volunteers Undergoing Unilateral Lower Limb Immobilization (ULLI)
Healthy Volunteers
Juvena Therapeutics36 enrolled2 locationsNCT07397468
Recruiting
Phase 1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants
Healthy Participants
Jazz Pharmaceuticals86 enrolled1 locationNCT07377539
Recruiting
Phase 1
A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants
Healthy Volunteer
AbbVie32 enrolled1 locationNCT07425899
Recruiting
Phase 1
Comparative Analysis of Biotinylated, Irradiated and 51-Chromium Radiolabeled Red Blood Cells for Analysis of Recovery and Survival After Autologous Transfusion
Healthy Volunteer Red Blood Cell Labeling Study; Not Disease Focused
Jose Cancelas20 enrolled2 locationsNCT07446647
Recruiting
Phase 1Phase 2
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Healthy VolunteersMetabolic dysfunction–associated steatotic liver disease (MASLD)
Regeneron Pharmaceuticals172 enrolled6 locationsNCT05648214
Recruiting
Phase 1
A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.
Healthy Volunteer
AbbVie24 enrolled1 locationNCT07514260
Recruiting
Phase 1
A Study of ORN252 in Healthy Participants
Healthy Volunteers - Male and Female
Orna Therapeutics, Inc.20 enrolled1 locationNCT07439796
Recruiting
Phase 1
A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participants
Healthy Participants
AstraZeneca42 enrolled1 locationNCT07241065
Recruiting
Phase 1
Study of BW-50218 in Healthy Participants
Healthy Participants Study
Shanghai Argo Biopharmaceutical Co., Ltd.60 enrolled2 locationsNCT07401472
Recruiting
Phase 1
A Study to Evaluate Single and Multiple Doses of TLC-1180 in Healthy Subjects
Healthy Participants
OrsoBio, Inc288 enrolled1 locationNCT07300189
Recruiting
Phase 1
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
Healthy Volunteer StudyRenal ImpairmentHepatic Impairment
Atea Pharmaceuticals, Inc.28 enrolled2 locationsNCT06911320
Recruiting
Phase 1
Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]GRT6019
Healthy male volunteers
Grünenthal GmbH10 enrolled1 locationNCT07479745
Recruiting
Phase 1
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
Healthy Volunteer Study
Atea Pharmaceuticals, Inc.32 enrolled3 locationsNCT07314346
Recruiting
Phase 1
A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SV003 in Healthy Participants.
Healthy Participants
Shanghai Synvida Biotechnology Co.,Ltd.60 enrolled1 locationNCT07469085
Recruiting
Phase 1
Single Ascending Dose Study of HB2198 in Healthy Participants
Healthy Volunteer
Hinge Bio32 enrolled1 locationNCT07439263
Recruiting
Phase 1
SAD and MAD Study of AKB-9090 in Healthy Adult Participants
Healthy Volunteers
Akebia Therapeutics70 enrolled1 locationNCT07429006
Recruiting
Phase 1
A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022)
Healthy
Merck Sharp & Dohme LLC24 enrolled1 locationNCT07232589
Recruiting
Phase 1
Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants
healthy adult participants
Alexion Pharmaceuticals, Inc.48 enrolled1 locationNCT07352423
Recruiting
Phase 1
A Study of [14C]-LY4064809 in Healthy Participants
Healthy
Eli Lilly and Company8 enrolled1 locationNCT07519525
Recruiting
Phase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
Healthy ParticipantsAtopic Dermatitis
Pfizer119 enrolled3 locationsNCT06564389